Jerry Griffin, VP of Sales & Marketing at BayMedica, Inc. – a subsidiary of InMed Pharmaceuticals Inc INM – was a guest on Benzinga’s All Access.
InMed is a clinical stage biopharma company that develops drugs based on rare cannabinoids. The company has several drugs in the development pipeline that target ailments as diverse as glaucoma and neurodegenerative diseases.
The company’s subsidiary, Baymedica, produces synthetic cannabinoids for the health and wellness sector.
Watch the full interview here:
Featured photo by Hans Reniers on Unsplash
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!